Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»
Until clinical trials of efficacy and safety are obtained, routine use of barycytinib in patients with COVID-19 cannot be recommended.
| 出版年: | Качественная клиническая практика |
|---|---|
| 主要な著者: | , , |
| フォーマット: | 論文 |
| 言語: | ロシア語 |
| 出版事項: |
Izdatelstvo OKI
2020-10-01
|
| 主題: | |
| オンライン･アクセス: | https://www.clinvest.ru/jour/article/view/517 |